Calidi Biotherapeutics to Host Investor Webinar on RedTail Platform and Oncology Advancements

Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotech company, will host an investor webinar on July 24, 2025, focusing on its RedTail platform and recent advancements in oncology. The webinar, led by CEO Eric Poma, Ph.D., will detail the company's systemically delivered viral therapy designed to treat metastatic tumors by evading immune detection. Calidi will present preclinical data on its lead candidate, CLD-401, which demonstrated tumor elimination and immune memory activation. The company is advancing toward an Investigational New Drug filing and exploring strategic pharmaceutical partnerships to facilitate commercialization. Following the presentation, attendees will have the opportunity to engage in a Q&A session. For more details, visit https://ibn.fm/zIp8d.

The investor webinar highlights the importance of Calidi's RedTail platform in addressing metastatic tumors, a significant challenge in oncology due to their spread and resistance to conventional treatments. By focusing on a systemically delivered viral therapy that evades immune detection, the company aims to overcome limitations of current therapies, potentially offering a more effective approach for patients with advanced cancer. The preclinical data on CLD-401, showing tumor elimination and immune memory activation, suggests promise in not only treating existing tumors but also preventing recurrence, which could improve long-term outcomes. This advancement matters as it represents a step forward in personalized cancer treatment, leveraging viral vectors to target hard-to-reach metastases.

Calidi's progress toward an Investigational New Drug filing indicates regulatory readiness and could accelerate clinical trials, bringing the therapy closer to patient use. The exploration of strategic pharmaceutical partnerships is crucial for scaling production and distribution, ensuring broader access if approved. The webinar provides investors and stakeholders with insights into the company's trajectory, emphasizing the potential impact on oncology care. As cancer remains a leading cause of death globally, innovations like Calidi's RedTail platform could transform treatment paradigms, offering hope for improved survival rates and quality of life. The implications extend beyond clinical benefits to economic and healthcare system efficiencies, reducing the burden of metastatic disease.

In summary, Calidi Biotherapeutics' webinar underscores the significance of its oncology advancements, with implications for cancer treatment innovation and patient care. The focus on immune evasion and systemic delivery addresses key gaps in current therapies, positioning the company as a potential leader in next-generation oncology solutions. For more information, refer to https://ibn.fm/zIp8d.